CN115298210A - 用于治疗慢性移植物抗宿主病的抗体 - Google Patents

用于治疗慢性移植物抗宿主病的抗体 Download PDF

Info

Publication number
CN115298210A
CN115298210A CN202080095646.6A CN202080095646A CN115298210A CN 115298210 A CN115298210 A CN 115298210A CN 202080095646 A CN202080095646 A CN 202080095646A CN 115298210 A CN115298210 A CN 115298210A
Authority
CN
China
Prior art keywords
csf
antibody
versus
host disease
chronic graft
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080095646.6A
Other languages
English (en)
Chinese (zh)
Inventor
P·欧尔德恩特里奇
M·迈尔斯
B·W·莫里森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syndax Pharmaceuticals Inc
Original Assignee
Syndax Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syndax Pharmaceuticals Inc filed Critical Syndax Pharmaceuticals Inc
Publication of CN115298210A publication Critical patent/CN115298210A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7153—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for colony-stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Transplantation (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202080095646.6A 2019-12-09 2020-12-09 用于治疗慢性移植物抗宿主病的抗体 Pending CN115298210A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962945842P 2019-12-09 2019-12-09
US62/945,842 2019-12-09
US202063110111P 2020-11-05 2020-11-05
US63/110,111 2020-11-05
PCT/US2020/064010 WO2021119128A1 (en) 2019-12-09 2020-12-09 Antibodies for the treatment of chronic graft versus host disease

Publications (1)

Publication Number Publication Date
CN115298210A true CN115298210A (zh) 2022-11-04

Family

ID=76330540

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080095646.6A Pending CN115298210A (zh) 2019-12-09 2020-12-09 用于治疗慢性移植物抗宿主病的抗体

Country Status (11)

Country Link
US (1) US12552869B2 (https=)
EP (1) EP4073100A4 (https=)
JP (1) JP2023506779A (https=)
KR (1) KR20220123004A (https=)
CN (1) CN115298210A (https=)
AU (1) AU2020401551A1 (https=)
CA (1) CA3164126A1 (https=)
IL (1) IL293705A (https=)
MX (1) MX2022007029A (https=)
PH (1) PH12022551401A1 (https=)
WO (1) WO2021119128A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20260013464A (ko) * 2023-05-17 2026-01-28 신닥스 파마슈티컬스, 인크. 항-콜로니 자극 인자 1 수용체 항체를 이용한 만성 이식편대숙주 질환-관련 폐쇄성 세기관지염 증후군의 치료 방법
CN121620392A (zh) * 2023-07-23 2026-03-06 因赛特公司 使用抗集落刺激因子1受体抗体治疗慢性移植物抗宿主病的方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105658236A (zh) * 2013-08-30 2016-06-08 Ucb生物制药私人有限公司 抗体
WO2018213665A1 (en) * 2017-05-19 2018-11-22 Syndax Pharmaceuticals, Inc. Combination therapies

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003210060B2 (en) 2002-03-22 2010-02-25 Aprogen, Inc. Humanized antibody and process for preparing same
WO2005014655A2 (en) 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
MY146381A (en) 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
JP2008526773A (ja) * 2004-12-30 2008-07-24 ドール バイオファーマ、インコーポレイテッド ベクロメタゾンジプロピオネート及びプレドニゾンでの、移植片対宿主病及び白血病の治療
WO2007142667A2 (en) 2005-10-13 2007-12-13 Human Genome Sciences, Inc. Treatment of patients with autoantibody positive disease
EP2076266A2 (en) 2006-05-31 2009-07-08 The Board of Trustees of the Leland Stanford Junior University Method of treating inflammatory diseases using tyroskine kinase inhibitors
WO2008055013A2 (en) 2006-10-31 2008-05-08 Janssen Pharmaceutica N.V. 5-oxo-5,8 - dihydro - pyrido - pyrimidines as inhibitors of c-fms kinase
PL2188313T3 (pl) 2007-08-21 2018-04-30 Amgen, Inc. Białka wiążące ludzki antygen c-fms
JO3240B1 (ar) 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
US20090148905A1 (en) 2007-11-30 2009-06-11 Claire Ashman Antigen-binding constructs
US8470977B2 (en) 2008-03-14 2013-06-25 Transgene S.A. Antibody against the CSF-1R
BRPI0909044B8 (pt) 2008-03-14 2021-05-25 Transgene Sa anticorpo que se liga especificamente ao csf-1r humano,composição farmacêutica e uso dos mesmos
WO2010012667A1 (en) 2008-08-01 2010-02-04 Santaris Pharma A/S Micro-rna mediated modulation of colony stimulating factors
ES2722300T3 (es) 2009-12-10 2019-08-09 Hoffmann La Roche Anticuerpos que se unen preferentemente al dominio extracelular 4 de CSF1R y su uso
US9169323B2 (en) 2010-03-05 2015-10-27 Hoffmann-La Roche Inc. Antibodies against human CSF-1R
JP5989547B2 (ja) 2010-03-05 2016-09-07 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ヒトｃｓｆ−１ｒに対する抗体及びその使用
EP2545078A1 (en) 2010-03-11 2013-01-16 UCB Pharma, S.A. Pd-1 antibody
AR080698A1 (es) 2010-04-01 2012-05-02 Imclone Llc Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e
HRP20190047T1 (hr) 2010-05-04 2019-02-22 Five Prime Therapeutics, Inc. Protutijela koja se vežu na csf1r
UA112425C2 (uk) 2010-12-13 2016-09-12 Еррей Біофарма Інк. ЗАМІЩЕНІ N-(1H-ІНДАЗОЛ-4-ІЛ)ІМІДАЗО[1,2-a]ПІРИДИН-3-КАРБОКСАМІДНІ СПОЛУКИ ЯК ІНГІБІТОРИ РЕЦЕПТОРНОЇ ТИРОЗИНКІНАЗИ ІІІ ТИПУ
WO2013057281A2 (en) 2011-10-21 2013-04-25 Transgene Sa Modulation of macrophage activation
RU2658603C2 (ru) 2011-12-15 2018-06-21 Ф.Хоффманн-Ля Рош Аг Антитела против человеческого csf-1r и их применения
KR20140127855A (ko) 2012-02-06 2014-11-04 제넨테크, 인크. Csf1r 억제제를 사용하는 조성물 및 방법
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
GB201315486D0 (en) 2013-08-30 2013-10-16 Ucb Pharma Sa Antibodies
ES2763309T3 (es) 2015-02-09 2020-05-28 UCB Biopharma SRL Formulación farmacéutica que comprende anticuerpos

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105658236A (zh) * 2013-08-30 2016-06-08 Ucb生物制药私人有限公司 抗体
WO2018213665A1 (en) * 2017-05-19 2018-11-22 Syndax Pharmaceuticals, Inc. Combination therapies

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KYLIE A ALEXANDER 等: "CSF-1-dependant donor-derived macrophages mediate chronic graft-versus-host disease", THE JOURNAL OF CLINICAL INVESTIGATION, vol. 124, no. 10, 26 August 2014 (2014-08-26), pages 4266 - 4280, XP055837036, DOI: 10.1172/JCI75935 *
SYNDAX PHARMACEUTICALS: "A Phase 1 Study to Evaluate SNDX- 6352 in Subjects With Active cGVD", pages 1 - 23, Retrieved from the Internet <URL:https://www.clinicaltrials.gov/study/NCT03604692?a=7&tab=history#version-content-panel> *
SYNDAX PHARMACEUTICALS: "NCT03604692:A Phase 1/2 Study to Evaluate SNDX-6352 in Participants With Active cGVHD", HTTPS://CLINICALTRIALS.GOV/STUDY/NCT03604692?COND=CHRONIC%20GRAFT-VERSUS-HOST%20DISEASE&TERM=AXATILIMAB&RANK=5, 27 July 2018 (2018-07-27), pages 1 - 15 *

Also Published As

Publication number Publication date
EP4073100A1 (en) 2022-10-19
KR20220123004A (ko) 2022-09-05
US12552869B2 (en) 2026-02-17
PH12022551401A1 (en) 2023-08-23
IL293705A (en) 2022-08-01
WO2021119128A1 (en) 2021-06-17
MX2022007029A (es) 2022-08-15
CA3164126A1 (en) 2021-06-17
JP2023506779A (ja) 2023-02-20
AU2020401551A1 (en) 2022-06-30
EP4073100A4 (en) 2024-02-14
US20230035183A1 (en) 2023-02-02

Similar Documents

Publication Publication Date Title
TW202319068A (zh) 用抗tim-3抗體治療癌症之方法
EP3581585A1 (en) Vedolizumab for the treatment of fistulizing crohn&#39;s disease
CN118924895A (zh) 用于癌症治疗的结合her2、nkg2d和cd16的多特异性结合蛋白的药物制剂和剂量方案
US20220178930A1 (en) Anti-galectin-9 antibodies and uses thereof
US20230131598A1 (en) Combination treatment for cancer
TW202237184A (zh) 抗cd19組合療法
JP2023515675A (ja) Ｐｄ－１アンタゴニスト、ｃｔｌａ４アンタゴニストおよびレンバチニブまたはその薬学的に許容される塩の組合せを用いる癌を治療する方法
JP2024156880A (ja) がんを処置するための抗ｌａｇ３抗体の投薬レジメンおよび抗ｐｄ－１抗体との組み合わせ治療
US20240043543A1 (en) Anti-galectin-9 antibodies and therapeutic uses thereof
US20230140694A1 (en) Combination treatment for cancer involving anti-icos and anti-pd1 antibodies, optionally further involving anti-tim3 antibodies
CN115298210A (zh) 用于治疗慢性移植物抗宿主病的抗体
KR20230095983A (ko) Gm-csf 길항제를 사용한 암의 치료
RU2745814C1 (ru) Водная фармацевтическая композиция левилимаба и ее применение
CN110582702A (zh) 使用il-17拮抗剂选择性治疗哮喘的方法
JP2023541921A (ja) Ｃｏｖｉｄ－１９肺炎を有する入院患者におけるトシリズマブの有効性及び安全性を評価するためのランダム化二重盲検プラセボ対照多施設試験（ｅｍｐａｃｔａ）の結果
US20260116977A1 (en) Methods of treating melanoma using an anti-ctla4 antibody
EA052089B1 (ru) Антитела для лечения хронического заболевания &#34;трансплантат против хозяина&#34;
US20230365691A1 (en) Use of anti-pd-1 antibody in treatment of nasopharyngeal carcinoma
JP2023504679A (ja) インターロイキン－１７（ｉｌ－１７）アンタゴニストを使用して扁平苔癬を治療する方法
WO2025085792A1 (en) Treatment of hematological malignancies with antibodies inhibiting galectin-9
JP2026513770A (ja) 抗ｃｔｌａ４抗体を使用して黒色腫を治療する方法
HK40121853A (zh) 用抑制半乳糖凝集素-9的抗体治疗血液恶性肿瘤

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination